Sep 2026· International Journal of Innovative Technologies in Social Science· 0 citations· 19 references
TL;DR
Current evidence indicates that AI can extract complementary biological information from complex circulating biomarker datasets, but prospective validation is still required before widespread implementation, and this review addresses major translational barriers.
Abstract
Liquid biopsy has emerged as an important minimally invasive technology in contemporary oncology, enabling repeated assessment of tumor-derived molecular information through blood and other biological fluids. Circulating tumor DNA (ctDNA), circulating tumor cells, cell-free DNA methylation patterns, extracellular vesicles, circulating RNA and fragmentomic signatures may provide dynamic information about tumor burden, treatment response, molecular residual disease and cancer recurrence. However, liquid biopsy generates complex, multidimensional datasets in which tumor-derived signals may be extremely small relative to biological and technical background. Artificial intelligence (AI), including machine learning and deep learning, offers a potential computational framework for integrating these heterogeneous signals and generating clinically meaningful predictions.
This review examines the emerging convergence of AI and liquid biopsy, with particular emphasis on longitudinal cancer monitoring rather than cancer detection alone. The available PubMed-indexed literature was reviewed to evaluate the potential role of AI-enhanced liquid biopsy in treatment-response assessment, minimal residual disease detection, prediction of treatment resistance and early identification of disease recurrence. Evidence from colorectal, lung, breast, hepatocellular and other solid tumors is discussed. The review also addresses major translational barriers, including low tumor shedding, clonal hematopoiesis, analytical heterogeneity, external validation, algorithmic bias, interpretability, data privacy, cost and uncertainty regarding clinical actionability. Current evidence indicates that AI can extract complementary biological information from complex circulating biomarker datasets, but prospective validation is still required before widespread implementation. AI-enhanced liquid biopsy may ultimately support a transition from episodic, imaging-centered surveillance toward personalized, dynamic and molecularly informed cancer monitoring.
This review critically examines whether longitudinal liquid-biopsy measurement, combined with artificial intelligence (AI), can move oncology from tumour monitoring toward genuine prediction of cancer evolution and treatment resistance.
Richard Afriyie Osei, Danmegoro Suleman Taiye, Godwin Kenechukwu Nwajiugo et al.· Oncology, Nuclear Medicine a...· 0 citations
The biological processes that influence ctDNA release, fragmentation, and clearance, including tumor cell turnover and cell death pathways, are discussed, as these directly affect its abundance in blood.
A multimodal decision matrix and an artificial intelligence (AI)-driven fusion pipeline integrating fragmentomics, EV proteomics, and CTC transcriptomics are introduced to enhance minimal residual disease detection and guide precision neuro-oncology.
Olawumi Giwa, Yonit Leykind, I. Altman et al.· Trends in Biotechnology· 0 citations
Lung cancer continues to be a predominant global cause of death. Clinical outcomes are significantly influenced by the timely identification of high-risk populations, accurate diagnosis, and appropriate therapy selection. Progress in artificial intelligence (AI), liquid biopsy, and immunotherapy has opened new avenues...
G. Pranowo, Gilang Prayoga Putra Permana, D. Selvyana· Indonesian Journal of Health...· 0 citations
Tissue biopsy and histopathological evaluation-considered the gold
standard-are traditionally used for cancer diagnosis; however, these procedures are invasive and
limited in their ability to accurately capture tumor heterogeneity. Liquid biopsy has emerged as
a minimally invasive alternative that enables molecular...
Ankur Vashishtha, Azeem Rizvi, Asif Ali et al.· Current Signal Transduction...· 0 citations
Bladder cancer (BC), as the most common form of urothelial carcinoma, represents a substantial global health burden owing to its high rates of late diagnosis and disease recurrence. Current standard diagnostics, such as cystoscopy and tissue biopsy, are invasive, costly, and limited in capturing tumor heterogeneity or...
Can Chen, Yu-Ze Yang, Zhou-Hui Chen et al.· Journal of Translational Med...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.